Objective To investigate the prognostic value of soluble growth stimulation expressed gene 2 protein (sST2) in patients with immune checkpoint inhibitor-associated myocarditis (ICIAM).
Methods From January 1, 2019 to December 31, 2020, 19 patients with ICIAM were selected from Cardio-oncology multidisciplinary team of Zhongshan Hospital, Fudan University. According to the prognosis, they were divided into the survival group (n=15) and the death group (n=4). Receiver operating characteristic (ROC) curve was used to analyze the predictive value of sST2 level for prognosis.
Results The peak concentration of sST2 in the death group was higher than that in the survival group during the treatment (156.5091.60, 410.60 ng/mL vs 54.6518.20, 97.40 ng/mL, P=0.014), and there was no significant difference in other indexes. The peak concentration of sST2 was negatively correlated with survival (r=-0.683, P=0.010). ROC analysis showed that when sST2 level was 87.5 ng/mL, area under the curve (AUC) was 0.967, sensitivity was 90.0%, and specificity was 100.0%.
Conclusions sST2 could predict the prognosis of patients with ICIAM, and could help to make and improve the treatment of patients with ICIAM.
DownLoad: